Kbio Labs

케이바이오랩스 · 038530

Consumer Staples Staples Retail · KOSDAQ

Small-cap

Market cap US$17.1M (₩23.6B)

Overview

Kbio Labs distributes laboratory reagents, instruments, and equipment used in life-science research, supplying universities, hospitals, and research facilities.

It also provides ICT products and services, including video-security hardware, software, and integrated monitoring solutions such as smart-city surveillance systems. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates two distinct business lines: a bio-distribution arm and an ICT arm built on video-security technology.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$63.3M

▲ +14.1% YoY

Operating profit · FY2025

US$1.1M

▲ +91.9% YoY

Net income · FY2025

−US$3.7M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$19.8M(₩27.3B)	US$55.4M(₩76.5B)	US$63.3M(₩87.3B)
Operating profit	−US$406.7K(−₩561.3M)	US$574.8K(₩793.2M)	US$1.1M(₩1.5B)
Net income	−US$9.2M(−₩12.7B)	−US$7.2M(−₩10B)	−US$3.7M(−₩5B)

Revenue

FY2023US$19.8M
FY2024US$55.4M
FY2025US$63.3M

Operating profit

FY2023−US$406.7K
FY2024US$574.8K
FY2025US$1.1M

Net income

FY2023−US$9.2M
FY2024−US$7.2M
FY2025−US$3.7M

Key ratios (FY2025)

ROE

-4.9%

Debt/Eq

16.2%

Op. margin

1.7%

Net margin

-5.8%

Rev. YoY

▲ +14.1%

Why it matters

The bio-distribution business was acquired from Cure Bio's distribution division and has operated for over two decades, giving it an established customer base in the Korean life-science supply chain.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?